Learn about atorvastatin-loaded PEGylated liposomes as a targeted therapeutic approach for treating ischemic stroke, focusing ...

The ReoPro Retavase Reperfusion of Stroke Safety Study (ROSIE) is an NIH-sponsored Phase II trial evaluating intravenous reteplase in combination with abciximab for the treatment of patients with ...

This study assesses acute ischemic stroke costs in Latin America, revealing treatment variations and economic challenges that ...

A medical device company developing technology to improve outcomes for stroke patients will begin enrollment for a new ...

The Microplasmin in Treatment of Ischemic Stroke – Intravenous (MITI-IV) trial, evaluated the safety and efficacy of intravenous microplasmin in 40 patients. There was no evidence of increased ...

Simcere Pharmaceutical announced that Sanbexin® sublingual tablets (generic name: edaravone and dexborneol sublingual tablets ...

NANJING, China, Dec. 4, 2024 /PRNewswire/ -- On November 2, 2024, Simcere Pharmaceutical announced that Sanbexin® sublingual tablets (generic name: edaravone and dexborneol sublingual tablets ...

Results from the trial showed that Revascor reduced cardiovascular mortality and major adverse cardiovascular events. Credit: ...

A TIA, or transient ischemic attack, is a temporary blockage of blood flow to a part of the brain. By definition, a TIA lasts ...

Hypoxic-ischemic encephalopathy (HIE ... s body temperature—called therapeutic hypothermia—is often used as a treatment. A review in Developmental Medicine and Child Neurology highlights ...

Hypoxic-ischemic encephalopathy (HIE) is one of the leading causes of newborn mortality and morbidity worldwide, and lowering ...

This product is indicated for the improvement of neurological symptoms, daily activities, and functional impairment due to acute ischemic stroke. Sanbexin ® sublingual tablets is a dual-target ...